Basic Information
| Drug ID | DDPD00479 |
|
| Drug Name | Amikacin | |
| Molecular Weight | 585.6025 | |
| Molecular Formula | C22H43N5O13 | |
| CAS Number | 37517-28-5 | |
| SMILES | NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O | |
| External Links | ||
| DRUGBANK | DB00479 | |
| PubChem Compound | 37768 | |
| PDR | 24277 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Boiling Point | 632.23 | ℃ | 632.23 | ℃ | https://www.chemicalbook.com/ChemicalProductProperty_US_CB8146049.aspx |
| Melting Point | 214.0 | ℃ | 214 | ℃ | MSDS |
| Water Solubility | 50000.0 | mg/L | 50 | mg/ml | https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Product_Information_Sheet/a1774pis.pdf |
| pKa | 8.1 | - | 8.1 | - | http://www.druginfosys.com/drug.aspx?drugcode=45&type=1 |
| Log S | -0.5 | - | -0.5 | - | ADME Research, USCD: https://pubchem.ncbi.nlm.nih.gov/compound/amikacin#section=Solubility |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| C Max | 21000.0 | ng/ml | 17-25 | mcg/ml | normal,healthy; adults; | DRUGBANK | C Max | 38000.0 | ng/ml | 38.0 | mcg/ml | intravenous injection, IV; | DRUGBANK | C Max | 26000.0 | ng/ml | 26±4 | mcg/ml | intravenous infusion, IV in drop; RD, renal impairment, Renal disease，including uremia; | The Pharmacological Basis of Therapeutics |
| T Max | 1.4 | h | 0.75-2 | h | normal,healthy; adults; | DRUGBANK | T Max | 1.0 | h | 1 | h | intravenous injection, IV; | DRUGBANK |
| Clearance | 6.0 | L/h | 100.0 | ml/min | Plasma clearance; | DRUGBANK | Clearance | 5.6 | L/h | 94.0 | ml/min | Renal clearance; normal,healthy; | DRUGBANK | Clearance | 0.0780 | L/h/kg | 1.3±0.6 | ml/min/kg | Obesity ↓ ;Cystic fibrosis ↑ ; | The Pharmacological Basis of Therapeutics | Clearance | 0.0660 | L/h/kg | 1.1 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 24.0 | L | 24.0 | L | normal,healthy; Male, men; | DRUGBANK | Volume of Distribution | 0.27 | L/kg | 0.27±0.06 | L/kg | Neonates ↑ ;Children → ;Elderly → ;Obesity ↓ ;Cystic fibrosis → ; | The Pharmacological Basis of Therapeutics | Volume of Distribution | 0.16 | L/kg | 0.16 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 2.5 | h | 2-3 | h | elimination half-life; adults; normal renal function; | DRUGBANK | Half-life | 58.0 | h | 30-86 | h | elimination half-life; adults; severe renal function; | DRUGBANK | Half-life | 2.3 | h | 2.3±0.4 | h | Children → ;RD, renal impairment, Renal disease，including uremia ↑ ;Obesity → ;Burn → ;Cystic fibrosis → ; | The Pharmacological Basis of Therapeutics | Half-life | 2.4 | h | 2.4 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LD50 | 6000.0 | mg/kg | 6000.0 | mg/kg | PO, oral; mouse; | DRUGBANK | |
| Eliminate Route | 96.0 | % | 94-98 | % | Urinary excretion; adults; human, homo sapiens; | DRUGBANK | Eliminate Route | 98.0 | % | 98 | % | Urinary excretion; Unchanged drug; | The Pharmacological Basis of Therapeutics |
| Protein Binding | 10.0 | % | ≤10 | % | DRUGBANK | Protein Binding | 4.0 | % | 4±8 | % | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for neonates | 15.0 | mg/kg/day | 15 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for neonates | 15.0 | mg/kg/day | 15 | mg/kg/dose | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for neonates | 15.0 | mg/kg/day | 15 | mg/kg/dose | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for neonates | 16.5 | mg/kg/dose | 16.5 | mg/kg/dose | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for infants | 15.0 | mg/kg/day | 15 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for infants | 22.5 | mg/kg/day | 22.5 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for infants | 35.0 | mg/kg/day | 35 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for children | 15.0 | mg/kg/day | 15 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for children | 1500.0 | mg/day | 1.5 | g/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for children | 22.5 | mg/kg/day | 22.5 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for children | 35.0 | mg/kg/day | 35 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for adolescents | 15.0 | mg/kg/day | 15 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for adolescents | 1500.0 | mg/day | 1.5 | g/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for adolescents | 22.5 | mg/kg/day | 22.5 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for adolescents | 35.0 | mg/kg/day | 35 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for adults | 15.0 | mg/kg/day | 15 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for adults | 1500.0 | mg/day | 1.5 | g/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for adults | 20.0 | mg/kg/day | 20 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for adults | 35.0 | mg/kg/day | 35 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for adults | 590.0 | mg/day | 590 | mg/day | inhalation, IH | Arikayce | amikacin liposome | PDR |
| Max dose for geriatric | 15.0 | mg/kg/day | 15 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for geriatric | 1500.0 | mg/day | 1.5 | g/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for geriatric | 20.0 | mg/kg/day | 20 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for geriatric | 35.0 | mg/kg/day | 35 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Arikayce | amikacin liposome | PDR |
| Max dose for geriatric | 590.0 | mg/day | 590 | mg/day | inhalation, IH | Arikayce | amikacin liposome | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1